Skip to content

Study of antiviral nutraceutical PICOVRID in COVID 19 patients

Evaluation of clinical efficacy of antiviral nutraceutical PICOVRID in COVID-19 positive patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026534
Enrollment
70
Registered
2020-07-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: PICOVRID syrup along with standard care: PICOVRID syrup 10 ml once a day along with standard care for 14 days Control Intervention1: Standard care: Standard care for 14 days

Sponsors

Indian Institute of Technology Bombay
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Individuals COVID-19 positive in last 3 days 2. Patients with mild COVID-19 illness as defined in the MOHFW guidelines i.e. fever and or upper respiratory tract infection ,influenza like illness 3. Patients agreeing to provide a written informed consent 4. Patients who agree to reside in the COVID 19 facility during the study

Exclusion criteria

Exclusion criteria: 1. Patients with moderate or severe COVID 19 at the time of recruitment 2. Patients not able to consume drugs orally 3. Patients with uncontrolled hypertension or diabetes mellitus 4. Patients with decompensated liver disease or renal disease 5. Pregnancy or lactation 6. Patients with multiorgan failure 7. Patients undergoing home quarantine during treatment of mild or very mild COVID 19

Design outcomes

Primary

MeasureTime frame
1.Reduction of viral load , indicated by increase in cycle threshold in nasopharyngeal and throat swabs by RT PCR on day 5, 7, 14 as compared to on admission 2.Time taken for clinical cure defined as Normalization of pyrexia and body pain Respiratory rate less than 24 per minute SpO2 rate more than 94 percent Relief from cough Relief from anosmia, for a period of 72 hour 3.Proportion of patients with swabs negative for SARS-nCOV on day 5, 7 Timepoint: Day 5, 7, 14.

Secondary

MeasureTime frame
1. Number of patients who progressed to moderate or severe category of COVID-19 on day 7 and day 14. 2. Number of patients having elevated CRP levels on day 7Timepoint: Day 7, 14

Countries

India

Contacts

Public ContactDr Rinti Banerjee

Indian Institute of Technology,Bombay.

rintibanerjee@gmail.com98196322131

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026